August 2021 Top Biopharma Deal: RemeGen – Seagen HER2-targeted ADC, Disitamab Vedotin for Solid Tumors
Top Biopharma Partnership by Upfront Cash and Equity
RemeGen development and commercialization deal with Seagen for disitamab vedotin
Announced: August 9, 2021
Total Deal Value: $2,600M
Upfront Cash: $200M
Upfront Equity: n/a
Option Payments: n/a
Milestones: $2,400M (Dev., Reg., and Sales)
Royalty: Tiered, high single-digit to mid-teens
Cost and Profit Split: n/a
Phase II HER2-targeted ADC disitamab vedotin for the treatment of several solid tumor types including urothelial, gastric, and breast cancer.
Development and Commercial License
Development responsibility and costs split by territory.
- RemeGen granted Seagen exclusive, worldwide rights, excluding parts of Asia, to co-develop and commercialize HER2-targeted ADC, disitamab vedotin for the treatment of several solid tumor types including urothelial, gastric, and breast cancer.
- RemeGen will retain development and commercialization rights in Asia excluding Japan and Singapore and will be responsible for all submissions specific to its territory.
- Seagen will lead global clinical development and RemeGen will fund and operate clinical trials attributable to its territory.
- RemeGen will receive $200M up front and is eligible for up to $2.4B in development, regulatory, and commercialization milestones, plus undisclosed tiered, high single-digit to mid-teens royalties.
The Deal of the Month for July 2021 was Arvinas and Pfizer’s PROTAC deal with $1B up front for ARV-471. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Want data for your analysis? Want us to do it? Subscribers get both.
Schedule your demo of the DealForma database to see how we help you get better reports done faster.
Specifically for Biotech, Pharma, Device, and Diagnostics
Get more done.
Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.
More Research by DealForma
Biotech and pharma deals in 2020 soared to an all-time high of 1,154 signed deals with $146.3 billion in total value, defying expectations that the global Covid-19 pandemic would hamper dealmaking. Global healthcare and life sciences R&D partnership activity was up 23 percent over 2019 and total deal values rose 31 percent from the previous year, driven in part by advances in technological and molecular understandings of disease pathways, and a drive toward targeted precision medicines.
Vir Biotechnology and GSK expanded their partnership with a new deal to develop VIR-2482 and mAbs for influenza. This was the largest upfront cash and equity for a partnership signed in Feb. 2021.
Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. We look at the extensive DealForma database to see how life sciences M&A activity shaped up in 2020 in more detail.
This article is a sample from the DealForma Annual Deal Trends Report provided to database subscribers. Data for this analysis was compiled using the DealForma biopharma deals database. We applied initial filters for mergers and acquisitions, therapeutic areas, asset...
Over the last three years, there have been eight M&A deals for companies developing advanced first generation and next gen cancer cell therapies. Six of them have been completed to date.
We looked at 10 years of gene therapy deals, M&A, venture funding, and academic partnerships for an article by John Carroll at Endpoints News.
Biotech reverse mergers have been an alternate way for private biotechnology companies to gain a public listing. Here’s a quick table of over 10 years of deals.
2019 biopharma dealmaking started with a bang as the first quarter saw global biotech and pharma partnering deal values hit $38 billion in 282 deals.
Celgene was among the top investors in cancer biotech companies. This is a look at the top 10 since 2010.
Life Sciences M&A started with a bang in 2019 with one of the biggest deals to date – Bristol-Myers Squibb will acquire Celgene for $74 billion. We mined DealForma’s extensive database for historical M&A trends in biopharma, medical devices, and diagnostics to get an idea of what might lie ahead in 2019.
You met on Zoom. Now it's Deal Time.
With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.